WealthAi | $1,000,000 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
Certified by Founder
Lodge
Syremis Therapeutics
start up
- 19/12/2025
- Series A
- $165,000,000
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.
- Industry Biotechnology Research
- Website https://syremis.com/
- LinkedIn https://www.linkedin.com/company/syremis-therapeutics/
Related People
Elisabeth KoganFounder
Israel -
ND
CEO and Co-founder of Syremis Therapeutics, a Biotech company developing novel therapies for neuropsychiatric conditions.
Experienced Pharma executive with a successful track record of delivering innovation and growth in the pharmaceutical industry.
Passionate about bringing new solutions to patients to reduce suffering and improve quality of life.
Mesh Security | $12,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Redwood Materials | $425,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
heyData | $16,500,000 | (Jan 30, 2026)